Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Two decades ago, WHO declared tuberculosis a global emergency, and invested in the
highly cost-effective directly observed treatment short-course programme to control the …

Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial
limitations, in terms of their effectiveness, side-effect profile, and complexity of …

Multidrug-and extensively drug-resistant (M/XDR) tuberculosis (TB) are emerging public
health concerns [ 1, 2]. In 2011, the World Health Organization (WHO) estimated 12 million …

The innovative diagnostic tools recently validated are changing the traditional paradigms of
TB diagnosis, for too long based on sputum smear, culture, and drug susceptibility testing …

Multidrug-resistant tuberculosis (MDR-TB), defined as active TB cases infected by
Mycobacterium tuberculosis strains that are resistant to isoniazid and rifampicin (the two …

Phenothiazines are being repurposed for treatment of tuberculosis. We examined time-kill
curves of thioridazine and first-line drugs against log-growth-phase and semidormant bacilli …

Extensively drug-resistant tuberculosis (XDR-TB)(defined as TB caused by Mycobacterium
tuberculosis strains with in vitro resistance to isoniazid and rifampicin plus any …

Background Adverse events (AEs) among HIV-infected patients with multidrug-resistant
tuberculosis (MDR-TB) receiving anti-TB and antiretroviral treatments (ART) are under …

Background Childhood tuberculosis (TB) accounts for a significant proportion of the global
tuberculosis disease burden. However, current and previous efforts to develop better …